201 related articles for article (PubMed ID: 31633227)
21. Down-regulation of RCC1 sensitizes immunotherapy by up-regulating PD-L1 via p27
Zeng X; Zhong M; Yang Y; Wang Z; Zhu Y
J Cell Mol Med; 2021 Apr; 25(8):4136-4147. PubMed ID: 33630417
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.
Venkataraman S; Alimova I; Balakrishnan I; Harris P; Birks DK; Griesinger A; Amani V; Cristiano B; Remke M; Taylor MD; Handler M; Foreman NK; Vibhakar R
Oncotarget; 2014 May; 5(9):2355-71. PubMed ID: 24796395
[TBL] [Abstract][Full Text] [Related]
23. Long non-coding RNA PHACTR2-AS1 promotes tongue squamous cell carcinoma metastasis by regulating Snail.
Yuan F; Miao Z; Chen W; Wu F; Wei C; Yong J; Xiao C
J Biochem; 2020 Dec; 168(6):651-657. PubMed ID: 32702100
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic Targeting of BRD4 in Head Neck Squamous Cell Carcinoma.
Wu Y; Wang Y; Diao P; Zhang W; Li J; Ge H; Song Y; Li Z; Wang D; Liu L; Jiang H; Cheng J
Theranostics; 2019; 9(6):1777-1793. PubMed ID: 31037138
[TBL] [Abstract][Full Text] [Related]
25. Obovatol inhibits the growth and aggressiveness of tongue squamous cell carcinoma through regulation of the EGF‑mediated JAK‑STAT signaling pathway.
Duan M; Du X; Ren G; Zhang Y; Zheng Y; Sun S; Zhang J
Mol Med Rep; 2018 Aug; 18(2):1651-1659. PubMed ID: 29845251
[TBL] [Abstract][Full Text] [Related]
26. Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells.
Sui S; Zhang J; Xu S; Wang Q; Wang P; Pang D
Cell Death Dis; 2019 Apr; 10(5):331. PubMed ID: 30988278
[TBL] [Abstract][Full Text] [Related]
27. Bromodomain-containing protein 4 inhibition improves the efficacy of cisplatin and radiotherapy in oral squamous cell carcinoma by suppressing programmed cell death-ligand 1 expression.
Ren J
Basic Clin Pharmacol Toxicol; 2024 Feb; 134(2):272-283. PubMed ID: 38014458
[TBL] [Abstract][Full Text] [Related]
28. Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma.
Zhang W; Ge H; Jiang Y; Huang R; Wu Y; Wang D; Guo S; Li S; Wang Y; Jiang H; Cheng J
Cancer Lett; 2020 Jan; 469():510-523. PubMed ID: 31765738
[TBL] [Abstract][Full Text] [Related]
29. NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma.
Lu F; Zhao Y; Pang Y; Ji M; Sun Y; Wang H; Zou J; Wang Y; Li G; Sun T; Li J; Ma D; Ye J; Ji C
Cancer Lett; 2021 Jan; 497():178-189. PubMed ID: 33091534
[TBL] [Abstract][Full Text] [Related]
30. LUCAT1 as an oncogene in tongue squamous cell carcinoma by targeting miR-375 expression.
Zhang K; Wang Q; Zhong B; Gong Z
J Cell Mol Med; 2021 May; 25(10):4543-4550. PubMed ID: 33787082
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-4651 targets bromodomain-containing protein 4 to inhibit non-small cell lung cancer cell progression.
Zheng J; Zhang Y; Cai S; Dong L; Hu X; Chen MB; Zhu YH
Cancer Lett; 2020 Apr; 476():129-139. PubMed ID: 32081805
[TBL] [Abstract][Full Text] [Related]
32. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
[TBL] [Abstract][Full Text] [Related]
33. Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential.
Zhao L; Ren Y; Tang H; Wang W; He Q; Sun J; Zhou X; Wang A
Oncotarget; 2015 Dec; 6(42):44538-50. PubMed ID: 26517090
[TBL] [Abstract][Full Text] [Related]
34. MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor.
Li J; Huang H; Sun L; Yang M; Pan C; Chen W; Wu D; Lin Z; Zeng C; Yao Y; Zhang P; Song E
Clin Cancer Res; 2009 Jun; 15(12):3998-4008. PubMed ID: 19509158
[TBL] [Abstract][Full Text] [Related]
35. Soluble PD-L1 Concentration Is Proportional to the Expression of PD-L1 in Tissue and Is Associated with a Poor Prognosis in Esophageal Squamous Cell Carcinoma.
Shiraishi T; Toyozumi T; Sakata H; Murakami K; Kano M; Matsumoto Y; Yokoyama M; Okada K; Kamata T; Ryuzaki T; Kinoshita K; Hirasawa S; Matsubara H
Oncology; 2022; 100(1):39-47. PubMed ID: 34991094
[TBL] [Abstract][Full Text] [Related]
36. Negative prognostic behaviour of PD-L1 expression in tongue and larynx squamous cell carcinoma and its significant predictive power in combination with PD-1 expression on TILs.
Ahmadvand S; Norouzi LA; Mohammadi Y; Safaei A; Khademi B; Motiee-Langroudi M; Ghaderi A
BMC Immunol; 2024 Jan; 25(1):7. PubMed ID: 38229027
[TBL] [Abstract][Full Text] [Related]
37. lncRNA RPSAP52 induced the development of tongue squamous cell carcinomas via miR-423-5p/MYBL2.
Wu X; Gong Z; Ma L; Wang Q
J Cell Mol Med; 2021 May; 25(10):4744-4752. PubMed ID: 33787061
[TBL] [Abstract][Full Text] [Related]
38. Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.
Zhou C; Che G; Zheng X; Qiu J; Xie Z; Cong Y; Pei X; Zhang H; Sun H; Ma H
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2663-2674. PubMed ID: 31541338
[TBL] [Abstract][Full Text] [Related]
39. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
40. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]